This company has been marked as potentially delisted and may not be actively trading. TenX Keane Acquisition (TENK) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsOwnershipTrendsBuy This Stock TENK vs. IKT, FTLF, ALTS, FATE, NMRA, IMRX, NKTX, RAPT, GLSI, and ACTUShould you be buying TenX Keane Acquisition stock or one of its competitors? The main competitors of TenX Keane Acquisition include Inhibikase Therapeutics (IKT), FitLife Brands (FTLF), ALT5 Sigma (ALTS), Fate Therapeutics (FATE), Neumora Therapeutics (NMRA), Immuneering (IMRX), Nkarta (NKTX), Rapt Therapeutics (RAPT), Greenwich LifeSciences (GLSI), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry. TenX Keane Acquisition vs. Its Competitors Inhibikase Therapeutics FitLife Brands ALT5 Sigma Fate Therapeutics Neumora Therapeutics Immuneering Nkarta Rapt Therapeutics Greenwich LifeSciences Actuate Therapeutics TenX Keane Acquisition (NASDAQ:TENK) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation. Do analysts recommend TENK or IKT? Inhibikase Therapeutics has a consensus target price of $6.50, indicating a potential upside of 225.00%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Inhibikase Therapeutics is more favorable than TenX Keane Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TenX Keane Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals and insiders believe in TENK or IKT? 70.5% of TenX Keane Acquisition shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 22.9% of TenX Keane Acquisition shares are owned by company insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer TENK or IKT? In the previous week, Inhibikase Therapeutics' average media sentiment score of 0.37 beat TenX Keane Acquisition's score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment TenX Keane Acquisition Neutral Inhibikase Therapeutics Neutral Is TENK or IKT more profitable? TenX Keane Acquisition's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TenX Keane AcquisitionN/A N/A N/A Inhibikase Therapeutics N/A -350.63%-201.82% Which has preferable earnings & valuation, TENK or IKT? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenX Keane AcquisitionN/AN/AN/AN/AN/AInhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.75 SummaryTenX Keane Acquisition and Inhibikase Therapeutics tied by winning 4 of the 8 factors compared between the two stocks. Get TenX Keane Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TENK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TENK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENK vs. The Competition Export to ExcelMetricTenX Keane AcquisitionHolding Offices Industry SectorNASDAQ ExchangeMarket Cap$21.62M$178.65M$2.01B$9.04BDividend YieldN/A5.38%13.71%4.04%P/E RatioN/A2.4812.2520.14Price / SalesN/A412.692,671,753.3398.20Price / CashN/A74.7861.1358.41Price / BookN/A6.153.265.60Net IncomeN/A$3.67M-$462.58M$248.43M TenX Keane Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENKTenX Keane AcquisitionN/A$3.25-25.1%N/A-61.8%$21.62MN/A0.00N/AHigh Trading VolumeIKTInhibikase Therapeutics1.3092 of 5 stars$1.85-5.1%$6.50+251.4%+52.7%$137.53M$260K-0.696FTLFFitLife Brands4.0598 of 5 stars$13.61-3.7%$20.50+50.6%-18.1%$132.79M$64.47M16.2020News CoverageALTSALT5 Sigma0.0683 of 5 stars$7.88+4.1%N/AN/A$132.04M$12.53M0.00170FATEFate Therapeutics4.288 of 5 stars$1.12-1.8%$3.83+242.3%-62.8%$130.65M$13.63M-0.75550NMRANeumora Therapeutics2.2027 of 5 stars$0.78-1.8%$9.29+1,087.1%-90.1%$128.80MN/A-0.49108News CoverageIMRXImmuneering4.0568 of 5 stars$3.59+4.4%$13.25+269.1%+223.1%$123.79M$320K-1.8360Positive NewsNKTXNkarta2.3959 of 5 stars$1.74+1.8%$14.33+723.8%-67.2%$121.34MN/A-1.15140News CoverageRAPTRapt Therapeutics4.4177 of 5 stars$8.01+9.3%$24.00+199.6%-67.9%$121.21M$1.53M-0.4280Analyst ForecastGLSIGreenwich LifeSciences1.5482 of 5 stars$9.88+9.2%$39.00+294.7%-28.9%$120.98MN/A-7.843ACTUActuate Therapeutics1.9983 of 5 stars$6.74+10.0%$20.50+204.2%N/A$120.27MN/A0.0010Positive NewsHigh Trading Volume Related Companies and Tools Related Companies IKT Alternatives FTLF Alternatives ALTS Alternatives FATE Alternatives NMRA Alternatives IMRX Alternatives NKTX Alternatives RAPT Alternatives GLSI Alternatives ACTU Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENK) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TenX Keane Acquisition Please log in to your account or sign up in order to add this asset to your watchlist. Share TenX Keane Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
